About Catalyst Pharmaceuticals (NASDAQ:CPRX)
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:CPRX
- CUSIP: N/A
- Web: www.catalystpharma.com
- Market Cap: $233.37 million
- Outstanding Shares: 84,554,000
- 50 Day Moving Avg: $2.56
- 200 Day Moving Avg: $2.44
- 52 Week Range: $0.94 - $3.20
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -11.04
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.40 per share
- Price / Book: 6.90
- EBITDA: ($16,440,000.00)
- Return on Equity: -44.65%
- Return on Assets: -42.03%
- Current Ratio: 19.43%
- Quick Ratio: 19.43%
- Average Volume: 569,288 shs.
- Beta: 1.59
- Short Ratio: 5.67
Frequently Asked Questions for Catalyst Pharmaceuticals (NASDAQ:CPRX)
What is Catalyst Pharmaceuticals' stock symbol?
Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."
How were Catalyst Pharmaceuticals' earnings last quarter?
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its earnings results on Wednesday, August, 9th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. View Catalyst Pharmaceuticals' Earnings History.
When will Catalyst Pharmaceuticals make its next earnings announcement?
Where is Catalyst Pharmaceuticals' stock going? Where will Catalyst Pharmaceuticals' stock price be in 2017?
4 brokerages have issued 1-year price objectives for Catalyst Pharmaceuticals' stock. Their predictions range from $5.00 to $6.00. On average, they anticipate Catalyst Pharmaceuticals' share price to reach $5.50 in the next year. View Analyst Ratings for Catalyst Pharmaceuticals.
Are investors shorting Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals saw a drop in short interest during the month of September. As of September 15th, there was short interest totalling 4,220,460 shares, a drop of 35.4% from the August 31st total of 6,532,907 shares. Based on an average daily volume of 856,492 shares, the short-interest ratio is currently 4.9 days. Currently, 5.9% of the shares of the stock are sold short.
Who are some of Catalyst Pharmaceuticals' key competitors?
Some companies that are related to Catalyst Pharmaceuticals include Progenics Pharmaceuticals (PGNX), Atara Biotherapeutics (ATRA), Seres Therapeutics (MCRB), Mersana Therapeutics (MRSN), Corbus Pharmaceuticals Holdings (CRBP), Kura Oncology (KURA), BioCryst Pharmaceuticals (BCRX), AVEO Pharmaceuticals (AVEO), NantKwest (NK), CymaBay Therapeutics (CBAY), UROGEN PHARMA (URGN), Bellicum Pharmaceuticals (BLCM), RA PHARMCTL INC (RARX), GlycoMimetics (GLYC), BioSpecifics Technologies Corp (BSTC), Merus N.V. (MRUS), Geron Corporation (GERN) and Edge Therapeutics (EDGE).
Who are Catalyst Pharmaceuticals' key executives?
Catalyst Pharmaceuticals' management team includes the folowing people:
- Patrick James McEnany, Chairman of the Board, President, Chief Executive Officer
- Alicia Grande CPA, Chief Financial Officer, Vice President, Treasurer
- Steven R. Miller Ph.D., Chief Operating Officer, Chief Scientific Officer
- David D. Muth, Executive Vice President, Chief Commercial Officer
- M. Douglas Winship, Vice President - Regulatory Operations
- David J. Caponera, Vice President - Patient Advocacy & Reimbursement
- Bernardino Mosquera M.D., Vice President - Clinical Operations
- Charles B. O'Keeffe, Lead Independent Director
- Gary Ingenito M.D., Chief Medical Officer
- Richard J. Daly, Director
How do I buy Catalyst Pharmaceuticals stock?
Shares of Catalyst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Catalyst Pharmaceuticals' stock price today?
MarketBeat Community Rating for Catalyst Pharmaceuticals (NASDAQ CPRX)MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Catalyst Pharmaceuticals stock can currently be purchased for approximately $2.76.
Consensus Ratings for Catalyst Pharmaceuticals (NASDAQ:CPRX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||4 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$5.50 (99.28% upside)|Consensus Price Target History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Analysts' Ratings History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/5/2017||SunTrust Banks, Inc.||Reiterated Rating||Buy||$5.00||High|
|8/10/2017||Roth Capital||Set Price Target||Buy||$5.00||Low|
|8/7/2017||Piper Jaffray Companies||Set Price Target||Buy||$6.00||Low|
|3/20/2017||HC Wainwright||Reiterated Rating||Buy||$6.00||Low|
Earnings History for Catalyst Pharmaceuticals (NASDAQ:CPRX)Earnings History by Quarter for Catalyst Pharmaceuticals (NASDAQ CPRX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)
2017 EPS Consensus Estimate: ($0.24)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Insider Ownership Percentage: 8.79%Insider Trades by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Institutional Ownership Percentage: 40.10%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/5/2017||Patrick J Mcenany||Insider||Buy||20,000||$2.58||$51,600.00|| |
|7/12/2016||Charles B O'keeffe||Director||Buy||20,000||$0.81||$16,200.00|| |
|6/17/2016||Philip H Coelho||Director||Buy||15,000||$0.76||$11,400.00|| |
|6/14/2016||Donald A Denkhaus||Director||Buy||50,000||$0.65||$32,500.00|| |
|6/14/2016||Patrick J Mcenany||CEO||Buy||105,300||$0.65||$68,445.00|| |
|4/26/2016||Charles B O'keeffe||Director||Buy||20,000||$0.60||$12,000.00|| |
|4/26/2016||Patrick J Mcenany||CEO||Buy||50,000||$0.65||$32,500.00|| |
|3/17/2016||Philip H Coelho||Director||Buy||10,000||$1.06||$10,600.00|| |
|3/16/2016||Charles B O'keeffe||Director||Buy||10,000||$1.11||$11,100.00|| |
|1/11/2016||Steve Miller||COO||Buy||7,933||$1.80||$14,279.40|| |
|1/8/2016||Charles B O'keeffe||Director||Buy||5,000||$1.94||$9,700.00|| |
|1/7/2016||Donald A Denkhaus||Director||Buy||25,000||$2.03||$50,750.00|| |
|12/28/2015||Patrick J Mcenany||CEO||Buy||25,000||$2.39||$59,750.00|| |
|12/23/2015||Charles B O'keeffe||Director||Buy||5,000||$2.41||$12,050.00|| |
|11/19/2015||Charles B O'keeffe||Director||Buy||5,000||$2.30||$11,500.00|| |
|10/23/2015||M Douglas Winship||VP||Sell||22,800||$3.34||$76,152.00|| |
|10/1/2015||Patrick J Mcenany||CEO||Buy||10,000||$2.81||$28,100.00|| |
|5/1/2015||David D Muth||EVP||Buy||1,700||$3.20||$5,440.00|| |
|4/30/2015||Charles B O'keeffe||Director||Buy||10,000||$3.29||$32,900.00|| |
|4/28/2015||David D Muth||EVP||Buy||2,000||$3.55||$7,100.00|| |
|4/27/2015||Donald A Denkhaus||Director||Buy||15,000||$3.71||$55,650.00|| |
|4/27/2015||Patrick J Mcenany||CEO||Buy||5,000||$3.79||$18,950.00|| |
|4/24/2015||Charles B O'keeffe||Director||Buy||5,000||$3.80||$19,000.00|| |
|3/27/2015||Donald A Denkhaus||Director||Buy||5,000||$4.17||$20,850.00|| |
|1/20/2015||David D Muth||EVP||Buy||21,000||$2.96||$62,160.00|| |
|1/13/2015||Charles B O'keeffe||Director||Buy||10,000||$3.00||$30,000.00|| |
|1/8/2015||Patrick J Mcenany||CEO||Buy||50,000||$2.80||$140,000.00|| |
|10/3/2014||David D Muth||VP||Buy||10,000||$2.65||$26,500.00|| |
|6/4/2014||Steve Miller||COO||Buy||100,000||$2.17||$217,000.00|| |
|5/21/2014||Patrick Mcenany||CEO||Buy||25,000||$1.89||$47,250.00|| |
|5/19/2014||Charles O'keeffe||Director||Buy||10,000||$1.83||$18,300.00|| |
|4/16/2014||Charles O'keeffe||Director||Buy||5,000||$2.02||$10,100.00|| |
|2/7/2014||Patrick Mcenany||CEO||Buy||25,000||$1.82||$45,500.00|| |
|2/5/2014||Charles O'keeffe||Director||Buy||10,000||$1.81||$18,100.00|| |
|10/23/2013||David S Tierney||Director||Buy||8,000||$2.03||$16,240.00|| |
|10/21/2013||Charles B O'keeffe||Director||Buy||10,000||$1.84||$18,400.00|| |
|10/21/2013||Patrick J Mcenany||CEO||Buy||50,000||$1.59||$79,500.00|| |
|2/19/2013||Patrick J Mcenany||CEO||Buy||50,000||$0.46||$23,000.00|| |
|12/17/2012||Patrick J Mcenany||CEO||Buy||100,000||$0.45||$45,000.00|| |
|12/8/2012||Biomarin Pharmaceutical Inc||Major Shareholder||Buy||5,000,000||$0.75||$3,750,000.00|| |
|11/15/2012||Patrick J Mcenany||CEO||Buy||100,000||$0.42||$42,000.00|| |
|11/15/2012||Philip H Coelho||Director||Buy||24,000||$0.41||$9,840.00|| |
Headline Trends for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Latest Headlines for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Loading headlines, please wait.
Catalyst Pharmaceuticals (CPRX) Chart for Sunday, October, 22, 2017